cliapplication-hero.jpg

Clinical Application of
Assay-Directed Therapy

Clinical Application of Functional Profiling

The following table is a representation of predicted clinical outcomes for patients treated with agents found active in the laboratory using the EVA-PCD functional profile.

With performance characteristics borrowed from the studies described earlier, these analyses have a sensitivity of 78.4% and specificity of 90.1%.

  • Literature Reported Response Rate

  • Response Rate for Assay (+) Patients

  • Response Rate for Assay (–) Patients

  • Fold Advantage, Assay (+) vs Assay (–)

10%
46.0%
2.6%
17.6
30%
77.0%
9.3%
8.3
50%
88.9%
19.3%
4.6
70%
94.8%
35.8%
2.6

Literature Reported Response Rate

This column provides expected clinical response rate based on current literature reported response rates (pre-test expectation).

These range from a 10% expected response rate for malignancies such as melanoma or renal cell carcinoma, up to 70% expected response rate for diseases such as untreated ovarian cancer or breast cancer.

Response Rates for Assay Patients (+/–)

These columns to the right reflect the likelihood of clinical response for patients found sensitive or resistant (post-test expectation). The fold advantage of utilizing active drugs versus inactive drugs is provided on the right.
vivo-img.jpg
PUBLISHED PAPER

Ex Vivo Programmed Cell Death and Prediction of Response to Chemotherapy

by Robert A. Nagourney, MD

Since the earliest introduction of cytotonic chemotherapy, investigators have pursued laboratory techniques designed to match patients to available drugs.

Most of the work, published in the 1980s, reflected the prevailing view of cancer as a disease of dysregulated cell proliferation.

Papers.png

Published Papers

Papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death functional profiling assay, and effectiveness of new drugs and combinations.
Curves.png

Survival Curves

Comparing the survival of patients who tested sensitive to the agents they received, compared with those who were found resistant to the treatments that they received.
Information.png

Physician Information

Find out how you can receive specific information on how your patient's cancer cells will react to single agents, combinations and targeted therapies.